BUZZ-Genmab shares fall after cancer drug trial failed to meet endpoint

Reuters01-19
BUZZ-Genmab shares fall after cancer drug trial failed to meet endpoint

** Shares in Denmark's Genmab GMAB.CO fall around 6% after the drugmaker and its U.S. partner AbbVie ABBV.N said their phase 3 trial for a blood cancer drug failed to meet endpoint

** Epcoritamab failed to improve the survival rate in patients in the late-stage study, the companies say

** "We would view a small correction in the shares as a buying opportunity into Genmab as one of our top picks," Van Lanschot Kempen says

** J.P.Morgan says it is disappointing to see the failure of the EPCORE DLBCL-1 trial

** It expects the focus to remain on the more significant 1L DLBCL trial readout in mid-2026 where Genmab seems more confident on positive results

** U.S.-listed shares of Genmab lost more than 7% in afternoon trade on Friday

** If losses hold, Genmab shares will see their worst day since April

(Reporting by Elviira Luoma)

((Elviira.luoma@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment